Aromatic Alcohol Moiety Patents (Class 560/163)
  • Patent number: 9682059
    Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy or epilepsy-related syndrome.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: June 20, 2017
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9566261
    Abstract: The present invention relates to a composition for preventing or treating a memory loss related disease comprising a phenyl carbamate compound and a method for preventing or treating various diseases related to loss of memory therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating memory loss-related diseases such as dementia and Alzheimer's disease.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 14, 2017
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Publication number: 20150148524
    Abstract: A method for the synthesis of an amino acid analogue or a salt, solvate, derivative, isomer or tautomer thereof comprising the steps of: (i) subjecting an amino acid containing a metathesisable group to metathesis with a compound containing a complementary metathesisable group of formula (I) or (II): (Formulae (I), (II)) wherein R1 and R2 are independently selected from H and substituted or unsubstituted C1 to C4 alkyl; each R3 is either absent or independently selected from a heteroatom, a substituted or unsubstituted C1 to C20 alkyl, and a substituted or unsubstituted C1 to C20 alkyl group interrupted by one or more heteroatoms; and each X is independently selected from H and an effector molecule; in the presence of a reagent to catalyse the metathesis to form a dicarba bridge between the amino acid containing a metathesisable group and the compound containing a complementary metathesisable group; and (ii) reducing the dicarba bridge to form a saturated dicarba bridge, wherein the reagent used to catalyse s
    Type: Application
    Filed: July 8, 2013
    Publication date: May 28, 2015
    Inventors: Zhen Wang, Andrea Robinson, Nicolas Daniel Spiccia, William Roy Jackson
  • Patent number: 9029589
    Abstract: A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: May 12, 2015
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9029592
    Abstract: The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: May 12, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Keith R. Fandrick, Joe Ju Gao, Jason Alan Mulder, Nitinchandra D. Patel, Xingzhong Zeng
  • Patent number: 9024055
    Abstract: Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: May 5, 2015
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Keith R. Bley, Bernd Jandeleit
  • Publication number: 20150080400
    Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
    Type: Application
    Filed: April 30, 2013
    Publication date: March 19, 2015
    Applicant: TAKEDA GMBH
    Inventors: Angelika Hoffmeyer, Rainer Boer, Manuela Hessmann, Andreas Pahl, Torsten Dunkern, Simone Hartung, Christof Zitt, Jurgen Volz, Christiane Praechter, Mahindra Makhija, Hiteshkumar Jain, Sandip Gavade, Arati Prabhu, Manojkumar Tiwari, Ashish Keche, Sarvesh Patel
  • Patent number: 8957212
    Abstract: There is intended to provide the novel compounds which generate a base easily when irradiated with long wavelength light (active energy rays), a photobase generator containing the compounds and a photobase generation method, and the present invention relates to the compounds represented by the general formula [1], a photobase generator containing the compounds and a photobase generation method: (wherein, Ar represents any of groups with specific structures selected from the group consisting of an anthracenyl group, an anthraquinonyl group and a pyrenyl group; R1 and R2 each independently represent a hydrogen atom or a linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, or represent ones which can form an alicyclic ring containing nitrogen atom(s) or an aromatic ring containing nitrogen atom(s) together with a nitrogen atom to which they are bound, which the rings having 3 to 8 carbon atoms which may have a substituent, R3 and R4 each independently represent a hydrogen atom, a linear, branc
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: February 17, 2015
    Assignee: Wako Pure Chemical Industries, Ltd.
    Inventors: Ayako Kuramoto, Motoshige Sumino, Nobuhiko Sakai
  • Patent number: 8901316
    Abstract: Disclosed is a process for producing an aminoadamantane carbamate derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. A process for producing an acid addition salt of a compound represented by the Formula (II): or a solvate of the acid addition salt, wherein R1 and R2 are each independently hydrogen, substituted or unsubstituted alkyl or the like; R3 and R4 are each independently hydrogen, substituted or unsubstituted alkyl or the like; and R5 and R6 are each independently hydrogen, halogen, carboxy, nitro, substituted or unsubstituted alkyl or the like; which comprises separating an acid addition salt of a compound represented by the Formula (II) or a solvate of the acid addition salt by adding an acid to a mixture of syn isomer and anti isomer of a compound represented by the Formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined above, in the presence of a solvent.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: December 2, 2014
    Assignee: Shionogi & Co., Ltd.
    Inventors: Yutaka Nishino, Hideki Shimizu, Takayuki Tsuritani, Natsuko Suzuki, Mutsumi Takaki, Tatsuya Kobayashi, Hideaki Sakamoto
  • Publication number: 20140315952
    Abstract: The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 23, 2014
    Inventor: Ziqiang Gu
  • Patent number: 8853439
    Abstract: The invention relates to improved processes for the preparation of lacosamide. The invention also relates to a novel intermediate useful in the preparation of lacosamide. The invention also relates to process for the purification of lacosamide.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 7, 2014
    Assignee: Cadila Healthcare Limited
    Inventors: Bipin Pandey, Kalpesh Shah
  • Publication number: 20140243407
    Abstract: Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 28, 2014
    Applicant: Accorda Therapeutics, Inc.
    Inventors: Keith R. Bley, Bernd Jandeleit
  • Publication number: 20140128581
    Abstract: Provided are crystalline ?, ?-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the ?, ?-disubstituted amino acids and their salts; methods of making these, and methods of using these.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 8, 2014
    Applicant: Aileron Therapeutics, Inc.
    Inventors: Krzysztof Darlak, Noriyuki Kawahata, Sameer Ahmed Athamneh
  • Publication number: 20140073809
    Abstract: The present invention provides the preparation method for (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (formula X compound), the preparation methods for its intermediates (S)-1-(3-methoxyphenyl)-N,N-dimethyl-N—((S)-1-phenylethyl)ethanaminium (formula VI compound), (S)-1-(3-hydroxyphenyl)-N,N-dimethyl-N—((S)-1-phenylethyl)ethanaminium (formula VIII compound) and (S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N—((S)-1-phenylethyl)ethanaminium (formula IX compound), as well as the method for using above mentioned formula IX compound to prepare rivastigmine which can be used for the treatment of Alzheimer's disease. The preparation method for rivastigmine has a reasonable synthetic design with convenient source of raw materials and high total yield, and the product resulted has high chemical and optical purity, which makes it easy for large-scale. industrial production.
    Type: Application
    Filed: May 16, 2012
    Publication date: March 13, 2014
    Applicants: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Fuli Zhang, Zhezhou Yang, Chunbo Yang, Daoxin Chen, Zhiqing Yang, Rentong Sun, Hua Bai
  • Publication number: 20140039200
    Abstract: The present invention relates to chiral ligands deriving from ?- and ?-amino acids, and from metal complexes formed from the same. The ligands are useful with catalytic gold complexes, particularly Au(I) complexes.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 6, 2014
    Applicant: The University of Sussex
    Inventors: Eddy Michel Elie Viseux, Christopher Gallop, Mariusz Bobin
  • Patent number: 8623913
    Abstract: The invention is directed to a method of treating restless legs syndrome in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: January 7, 2014
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Susan Marie Melnick, Duncan Paul Taylor
  • Publication number: 20130345423
    Abstract: A new method for the synthesis of L-Glutamyl-?-D-Glutamic acid and its use in the synthesis of (2R)-((4S)-carboxy-4-(4,N-(((6S)-2-(hydroxymethyl)-4-oxo-3,4,7,8-tetrahydro-3H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino)benzamido)butanamido)pentanedioic acid, 1 are provided. Also provided is an efficient method for the isolation and purification of the trisodium salt of the abovementioned acid, 2, in a form suitable for long term storage and use in a parenteral dosing form.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 26, 2013
    Applicant: Onyx Pharmaceutical, Inc.
    Inventors: James Alan Kershen, Thomas Elliott Jacks, Andrew S. Thompson, Alexander James Bridges, Milind D. Choubal, Sean Mark Dalziel, James Robert Zeller
  • Publication number: 20130331589
    Abstract: Chemical compositions, lubricant compositions, and methods of using the same are provided. The lubricant composition may comprise at least on carrier. In certain methods, the lubricant composition may be provided to at least one surface, wherein the lubricant composition reduces a coefficient of friction of the at least one surface. In certain methods, the lubricant composition may be provided to at least one surface, wherein the lubricant composition reduces wear of the at least one surface.
    Type: Application
    Filed: June 7, 2012
    Publication date: December 12, 2013
    Applicant: THE CHARLES STARK DRAPER LABORATORY, INC.
    Inventors: Henry Raczkowski, D. Andrew Dineen, JR., Daniel D'Auge
  • Publication number: 20130209483
    Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.
    Type: Application
    Filed: November 30, 2012
    Publication date: August 15, 2013
    Applicant: SUTTER WEST BAY HOSPITALS
    Inventor: SUTTER WEST BAY HOSPITALS
  • Publication number: 20130211130
    Abstract: The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 15, 2013
    Applicant: Boehringer Ingelheim International Gmbh
    Inventors: Keith R. FANDRICK, Joe Ju GAO, Jason Alan MULDER, Nitinchandra D. PATEL, Xingzhong ZENG
  • Publication number: 20130197240
    Abstract: Disclosed is a process for producing an aminoadamantane carbamate derivative which is useful as a significant intermediate of an 11?HSD-1 inhibitor. A process for producing an acid addition salt of a compound represented by the Formula (II): or a solvate of the acid addition salt, wherein R1 and R2 are each independently hydrogen, substituted or unsubstituted alkyl or the like; R3 and R4 are each independently hydrogen, substituted or unsubstituted alkyl or the like; and R5 and R6 are each independently hydrogen, halogen, carboxy, nitro, substituted or unsubstituted alkyl or the like; which comprises separating an acid addition salt of a compound represented by the Formula (II) or a solvate of the acid addition salt by adding an acid to a mixture of syn isomer and anti isomer of a compound represented by the Formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined above, in the presence of a solvent.
    Type: Application
    Filed: August 8, 2011
    Publication date: August 1, 2013
    Applicant: SHIONOGI & CO., LTD.
    Inventors: Yutaka Nishino, Hideki Shimizu, Takayuki Tsuritani, Natsuko Suzuki, Mutsumi Takaki, Tatsuya Kobayashi, Hideaki Sakamoto
  • Publication number: 20130172504
    Abstract: The invention provide a new class of silicone-containing prepolymers containing ethylenically unsaturated groups and latent UV-activated free radical generating moieties. This class of silicone-containing prepolymer is capable of being actinically crosslinked in the presence of one or more hydrophilic vinylic monomers to form a silicone hydrogel material with a hydrophilic surface without post curing surface treatment. The present invention is also related to silicone hydrogel contact lenses made from this class of silicone-containing prepolymers and a vinylic monomer having a latent UV-activated free radical generating moiety.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 4, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20130165509
    Abstract: A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.
    Type: Application
    Filed: December 27, 2012
    Publication date: June 27, 2013
    Applicant: Bio-Pharm Solutions Co., Ltd.
    Inventor: Bio-Pharm Solutions Co., Ltd.
  • Publication number: 20130096337
    Abstract: A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.
    Type: Application
    Filed: December 5, 2012
    Publication date: April 18, 2013
    Applicant: Novartis AG
    Inventor: Novartis AG
  • Publication number: 20120302782
    Abstract: There is provided a process for preparing a carbamate compound, which is easy and commercially advantageous in that a carbamate compound can be produced with high yield from an amine compound and a carbonate compound. A process for preparing a carbamate compound which comprises the step of reacting an amine compound which has at least one amino group per molecule wherein the amine compound is selected from the group consisting of an aliphatic amine which may be substituted by an alicyclic group or an aromatic group or which may be interrupted by an alicyclic group or an aromatic group, and an alicyclic amine which may be substituted by an aliphatic group, with a carbonate compound in the presence of at least one organic solvent selected from the group consisting of a saturated cyclic hydrocarbon, an unsaturated cyclic hydrocarbon, and a non-cyclic ether by using a hydrolase.
    Type: Application
    Filed: January 6, 2011
    Publication date: November 29, 2012
    Inventors: Yasuhito Yamamoto, Yasutaka Yoshida, Mayumi Araki
  • Patent number: 8293786
    Abstract: Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: October 23, 2012
    Assignee: Alltranz Inc.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard, Stan Lee Banks
  • Publication number: 20120245226
    Abstract: The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 3, 2010
    Publication date: September 27, 2012
    Inventors: Sung James Lee, Susan Marie Melnick
  • Publication number: 20120214786
    Abstract: This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R6, R7, R8 have meanings given in the description.
    Type: Application
    Filed: August 17, 2011
    Publication date: August 23, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Henning PRIEPKE, Henri DOODS, Raimund KUELZER, Roland PFAU, Dirk STENKAMP, Benjamin PELCMAN, Robert ROENN
  • Publication number: 20120209022
    Abstract: The invention relates to improved processes for the preparation of lacosamide. The invention also relates to a novel intermediate useful in the preparation of lacosamide. The invention also relates to process for the purification of lacosamide.
    Type: Application
    Filed: September 23, 2010
    Publication date: August 16, 2012
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Bipin Pandey, Kalpesh Shah
  • Publication number: 20120196939
    Abstract: A (?)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or pro drug thereof, is useful as an anesthetic.
    Type: Application
    Filed: April 2, 2012
    Publication date: August 2, 2012
    Inventor: Thomas E. Jenkins
  • Publication number: 20120184762
    Abstract: Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for preparation of the intermediate.
    Type: Application
    Filed: December 28, 2011
    Publication date: July 19, 2012
    Applicant: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Publication number: 20120122970
    Abstract: The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): Compounds of Formula (I) and Formula (II) are especially suitable for insecticide treated nets and indoor residual spraying for mosquito control.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 17, 2012
    Inventors: Paul Carlier, Jeffrey Bloomquist, Sally Paulson, Eric Wong
  • Patent number: 8129428
    Abstract: The present invention includes insecticidal carbamates that are useful, for example, for the control of insects, such as mosquitoes, which can be used in applications where exposure to and/or contact with humans is likely. The insecticides of the present invention include phenyl N-methyl carbamates and compositions comprising them that exhibit species-selective inhibition of acetylcholinesterase (AChE) and are preferably toxic to mosquitoes but not humans. Of particular interest are compounds of Formula (I) and Formula (II): Compounds of Formula (I) and Formula (II) are especially suitable for insecticide treated nets and indoor residual spraying for mosquito control.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: March 6, 2012
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Paul Carlier, Jeffrey Bloomquist, Sally Paulson, Eric Wong
  • Publication number: 20120031047
    Abstract: A method for storing a transdermally/transmucosally absorbable preparation, comprising keeping a transdermally/transmucosally absorbable preparation enclosed in a container in a low oxygen atmosphere, the transdermally/transmucosally absorbable preparation comprising a drug whose molecule has an amino group substituted with a lower alkyl group.
    Type: Application
    Filed: August 2, 2011
    Publication date: February 9, 2012
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Tomohiro SHINODA, Takashi Yasukouchi, Yasunori Takada
  • Publication number: 20120022281
    Abstract: Disclosed herein are novel intermediates and process for large scale production of (S)-3-[(1-dimethylamino)ethyl]phenyl-N-ethyl-N-methyl-carbamate (rivastigmine) or its pharmaceutically acceptable salts employing the novel intermediates. Further provided are methods for producing the novel intermediates thereof.
    Type: Application
    Filed: August 25, 2009
    Publication date: January 26, 2012
    Applicant: Jubilant Life Sciences Limited
    Inventors: Shailendra Kumar Dubey, Vikas Bansal, Kamaljeet Pannu, Sushil Kumar Dubey
  • Publication number: 20110319416
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-E, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 29, 2011
    Applicant: EMORY UNIVERSITY
    Inventors: Stephen F. Traynelis, Dennis C. Liotta, Cara Mosley, Timothy M. Acker, Sommer Zimmerman
  • Publication number: 20110233048
    Abstract: There is intended to provide the novel compounds which generate a base easily when irradiated with long wavelength light (active energy rays), a photobase generator containing the compounds and a photobase generation method, and the present invention relates to the compounds represented by the general formula [1], a photobase generator containing the compounds and a photobase generation method: (wherein, Ar represents any of groups with specific structures selected from the group consisting of an anthracenyl group, an anthraquinonyl group and a pyrenyl group; R1 and R2 each independently represent a hydrogen atom or a linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, or represent ones which can form an alicyclic ring containing nitrogen atom(s) or an aromatic ring containing nitrogen atom(s) together with a nitrogen atom to which they are bound, which the rings having 3 to 8 carbon atoms which may have a substituent, R3 and R4 each independently represent a hydrogen atom, a linear, branc
    Type: Application
    Filed: December 1, 2009
    Publication date: September 29, 2011
    Applicant: WAKO PURE CHEMICAL INDUSTRIES, LTD.
    Inventors: Ayako Kuramoto, Motoshige Sumino, Nobuhiko Sakai
  • Publication number: 20110224455
    Abstract: The invention is to di-amido gellant that are suitable for use in consumer product compositions.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Inventors: Susana FERNANDEZ PRIETO, Johan Smets, Beatriu Escuder Gil, Juan Felipe Mira Vet Celades, Vincent Josep Nebot Carda
  • Publication number: 20110086409
    Abstract: A method for making a surfactant-based monolithic column is provided. The method comprises providing a mixture comprising at least one surfactant monomer, at least one crosslinker, at least one initiator, and at least one porogen and polymerizing the mixture to form the surfactant-based monolithic column. The present disclosure also provides a surfactant-based monolithic column, a method for separating molecules, and a process for preparing a surfactant monomer.
    Type: Application
    Filed: March 30, 2009
    Publication date: April 14, 2011
    Inventors: Shahab Ahmed Shamsi, Jun He, Congying Gu
  • Publication number: 20110071178
    Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.
    Type: Application
    Filed: April 16, 2010
    Publication date: March 24, 2011
    Applicant: Northeastern University
    Inventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
  • Publication number: 20110065040
    Abstract: The present invention provides a photoresist composition comprising a resin, an acid generator and a compound represented by the formula (I): wherein R1 represents a C2-C12 alkyl group which can have one or more hydroxyl groups, etc., R2 and R3 each independently represent a hydrogen atom, etc., R4, R5 and R6 each independently represent a hydrogen atom, etc., A1 represents a single bond or a C1-C2 alkylene group in which one or more —CH2— can be replaced by —O—.
    Type: Application
    Filed: September 13, 2010
    Publication date: March 17, 2011
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Tatsuro MASUYAMA, Mitsuhiro Hata
  • Publication number: 20100292346
    Abstract: A (?)-stereoisomer of formula (I): [insert formula (I) wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, useful as an anesthetic.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 18, 2010
    Inventor: Thomas E. Jenkins
  • Publication number: 20100286109
    Abstract: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.
    Type: Application
    Filed: July 22, 2010
    Publication date: November 11, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael R. Schrimpf, Kathleen H. Mortell, Diana L. Nersesian, Chih-Hung Lee, Bruce Clapham
  • Patent number: 7807738
    Abstract: A urea-urethane compound having one or more urea groups and one or more urethane groups in the molecular structure, the number of said urea groups (A) and the number of said urethane groups (B) satisfying the following numerical formula: 10?(A+B)?3 wherein each of A and B is an integer of 1 or more.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: October 5, 2010
    Assignee: Chemipro Kasei Kaisha, Ltd.
    Inventors: Kazuo Kabashima, Hiroshi Kobayashi, Tetsurou Iwaya
  • Publication number: 20100249107
    Abstract: This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms associated with the conversion from Mile Cognitive Impairment to dementia, e.g., Alzheimer's Disease (AD). The invention provides AD-associated mutations which are useful in the diagnosis, prognosis or therapeutic treatment of dementia, e.g., Alzheimer's Disease.
    Type: Application
    Filed: August 17, 2007
    Publication date: September 30, 2010
    Inventor: Jonathan Benjamin Singer
  • Publication number: 20100227921
    Abstract: Prodrugs of tapentadol with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with the tapentadol prodrugs are provided herein. Prodrugs having side chains of valine, leucine, isoleucine and glycine amino acids and mono-, di- and tripeptides thereof are preferred. Additionally, methods for avoiding or minimizing the adverse gastrointestinal side effects associated with tapentadol administration, as well as increasing the oral bioavailability of tapentadol are provided herein.
    Type: Application
    Filed: March 1, 2010
    Publication date: September 9, 2010
    Applicant: SHIRE LLC
    Inventors: Richard Franklin, Bernard T. Golding, Robert G. Tyson
  • Publication number: 20100197939
    Abstract: The invention provides a new enantioselective process for the preparation of (S)-pregabalin, or a pharmaceutical acceptable addition acid salt comprising: acid hydrolysis of the dioxolan ring of a chiral compound of general formula (I) to obtain compound of general formula (II); oxidation of compound (II) to obtain a compound of general formula (III) and transforming compound (III) into compound of general formula (IV); subjecting compound (IV) to basic hydrolysis to obtain a compound of general formula (V) which is reduced to obtain enantiomerically pure S-pregabalin. The invention also provides new chiral intermediates involved in the process.
    Type: Application
    Filed: July 17, 2008
    Publication date: August 5, 2010
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Rosa M. Ortuno, Sandra Izquierdo, Helmut Heinrich Buschmann, Antoni Torrens Jover, Monica Garcia Lopez
  • Publication number: 20100168229
    Abstract: A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 1, 2010
    Inventors: Christian Mathes, Michael Foulkes, Martin Kesselgruber
  • Patent number: 7745657
    Abstract: The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: June 29, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Mark L. Greenlee, Carol A. McVean, Robert S. Meissner, Gayle E. Taylor
  • Publication number: 20100145060
    Abstract: Embodiments of the invention provide a method of using Schwartz Reagent, Cp2Zr(H)Cl, without accumulating or isolating it. Methods provide mixtures of Cp2ZrCl2, reductants that selectively reduce Cp2ZrCl2, and substrates. After reaction of Cp2ZrCl2 and the reductant, an intermediate reduction product is formed, apparently Schwartz Reagent. The in situ Schwartz Reagent then selectively reduces certain functional groups on the substrate. Substrates include tertiary amides, tertiary benzamides, aryl O-carbamates, and heteroaryl N-carbamates, which are reduced to aldehydes, benzaldehydes, aromatic alcohols, and heteroaromatics, respectively. Compared to prior methods, reagents are inexpensive and stable, reaction times are short, and reaction temperature in certain cases is conveniently room temperature. It has been estimated that using the in situ method described herein instead of synthesized or commercially obtained Schwartz Reagent provides a 50% reduction in cost.
    Type: Application
    Filed: December 3, 2009
    Publication date: June 10, 2010
    Inventors: Yigang Zhao, Victor A. Snieckus